nevirapine has been researched along with Disease Exacerbation in 23 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watts, DH | 1 |
| Brown, ER | 1 |
| Maldonado, Y | 1 |
| Herron, C | 1 |
| Chipato, T | 1 |
| Reddy, L | 1 |
| Moodley, D | 1 |
| Nakabiito, C | 1 |
| Manji, K | 1 |
| Fawzi, W | 1 |
| George, K | 1 |
| Richardson, P | 1 |
| Zwerski, S | 1 |
| Coovadia, H | 1 |
| Fowler, M | 1 |
| Gupta-Wright, A | 1 |
| Wood, R | 1 |
| Bekker, LG | 1 |
| Lawn, SD | 1 |
| Munshi, SU | 1 |
| Panda, H | 1 |
| Holla, P | 1 |
| Rewari, BB | 1 |
| Jameel, S | 1 |
| Penazzato, M | 2 |
| Prendergast, AJ | 1 |
| Muhe, LM | 1 |
| Tindyebwa, D | 1 |
| Abrams, E | 1 |
| Guidozzi, F | 1 |
| Black, V | 1 |
| Mugyenyi, P | 4 |
| Walker, AS | 3 |
| Hakim, J | 3 |
| Munderi, P | 3 |
| Gibb, DM | 3 |
| Kityo, C | 3 |
| Reid, A | 3 |
| Grosskurth, H | 4 |
| Darbyshire, JH | 5 |
| Ssali, F | 3 |
| Bray, D | 2 |
| Katabira, E | 3 |
| Babiker, AG | 3 |
| Gilks, CF | 2 |
| Kabuye, G | 1 |
| Nsibambi, D | 2 |
| Kasirye, R | 1 |
| Zalwango, E | 1 |
| Nakazibwe, M | 1 |
| Kikaire, B | 1 |
| Nassuna, G | 1 |
| Massa, R | 1 |
| Fadhiru, K | 2 |
| Namyalo, M | 1 |
| Zalwango, A | 1 |
| Generous, L | 1 |
| Khauka, P | 2 |
| Rutikarayo, N | 1 |
| Nakahima, W | 1 |
| Mugisha, A | 1 |
| Todd, J | 1 |
| Levin, J | 1 |
| Muyingo, S | 1 |
| Ruberantwari, A | 1 |
| Kaleebu, P | 2 |
| Yirrell, D | 2 |
| Ndembi, N | 2 |
| Lyagoba, F | 2 |
| Hughes, P | 1 |
| Aber, M | 1 |
| Lara, AM | 2 |
| Foster, S | 2 |
| Amurwon, J | 2 |
| Wakholi, BN | 2 |
| Whitworth, J | 1 |
| Wangati, K | 1 |
| Amuron, B | 1 |
| Kajungu, D | 1 |
| Nakiyingi, J | 1 |
| Omony, W | 1 |
| Tumukunde, D | 1 |
| Otim, T | 1 |
| Kabanda, J | 1 |
| Musana, H | 1 |
| Akao, J | 1 |
| Kyomugisha, H | 1 |
| Byamukama, A | 1 |
| Sabiiti, J | 1 |
| Komugyena, J | 1 |
| Wavamunno, P | 1 |
| Mukiibi, S | 1 |
| Drasiku, A | 1 |
| Byaruhanga, R | 1 |
| Labeja, O | 1 |
| Katundu, P | 2 |
| Tugume, S | 2 |
| Awio, P | 1 |
| Namazzi, A | 1 |
| Bakeinyaga, GT | 1 |
| Katabira, H | 1 |
| Abaine, D | 1 |
| Tukamushaba, J | 1 |
| Anywar, W | 1 |
| Ojiambo, W | 1 |
| Angweng, E | 1 |
| Murungi, S | 2 |
| Haguma, W | 1 |
| Atwiine, S | 1 |
| Kigozi, J | 3 |
| Namale, L | 1 |
| Mukose, A | 1 |
| Mulindwa, G | 1 |
| Atwiine, D | 1 |
| Muhwezi, A | 1 |
| Nimwesiga, E | 1 |
| Barungi, G | 1 |
| Takubwa, J | 1 |
| Mwebesa, D | 1 |
| Kagina, G | 1 |
| Mulindwa, M | 1 |
| Ahimbisibwe, F | 1 |
| Mwesigwa, P | 1 |
| Akuma, S | 1 |
| Zawedde, C | 1 |
| Nyiraguhirwa, D | 1 |
| Tumusiime, C | 1 |
| Bagaya, L | 1 |
| Namara, W | 1 |
| Karungi, J | 1 |
| Kankunda, R | 1 |
| Enzama, R | 1 |
| Latif, A | 2 |
| Robertson, V | 2 |
| Chidziva, E | 1 |
| Bulaya-Tembo, R | 1 |
| Musoro, G | 1 |
| Taziwa, F | 1 |
| Chimbetete, C | 1 |
| Chakonza, L | 1 |
| Mawora, A | 1 |
| Muvirimi, C | 1 |
| Tinago, G | 1 |
| Svovanapasis, P | 1 |
| Simango, M | 1 |
| Chirema, O | 1 |
| Machingura, J | 1 |
| Mutsai, S | 1 |
| Phiri, M | 1 |
| Bafana, T | 1 |
| Chirara, M | 2 |
| Muchabaiwa, L | 2 |
| Muzambi, M | 2 |
| Mutowo, J | 1 |
| Chivhunga, T | 1 |
| Chigwedere, E | 1 |
| Pascoe, M | 1 |
| Warambwa, C | 1 |
| Zengeza, E | 1 |
| Mapinge, F | 1 |
| Makota, S | 1 |
| Jamu, A | 1 |
| Ngorima, N | 1 |
| Chirairo, H | 1 |
| Chitsungo, S | 1 |
| Chimanzi, J | 1 |
| Maweni, C | 1 |
| Warara, R | 1 |
| Matongo, M | 1 |
| Mudzingwa, S | 1 |
| Jangano, M | 1 |
| Moyo, K | 1 |
| Vere, L | 1 |
| Mdege, N | 1 |
| Machingura, I | 1 |
| Ronald, A | 1 |
| Kambungu, A | 1 |
| Lutwama, F | 1 |
| Mambule, I | 1 |
| Nanfuka, A | 1 |
| Walusimbi, J | 1 |
| Nabankema, E | 1 |
| Nalumenya, R | 1 |
| Namuli, T | 1 |
| Kulume, R | 1 |
| Namata, I | 1 |
| Nyachwo, L | 1 |
| Florence, A | 1 |
| Kusiima, A | 1 |
| Lubwama, E | 1 |
| Nairuba, R | 1 |
| Oketta, F | 1 |
| Buluma, E | 1 |
| Waita, R | 1 |
| Ojiambo, H | 1 |
| Sadik, F | 1 |
| Wanyama, J | 1 |
| Nabongo, P | 1 |
| Oyugi, J | 1 |
| Sematala, F | 1 |
| Muganzi, A | 1 |
| Twijukye, C | 1 |
| Byakwaga, H | 1 |
| Ochai, R | 1 |
| Muhweezi, D | 1 |
| Coutinho, A | 1 |
| Etukoit, B | 1 |
| Gilks, C | 2 |
| Boocock, K | 1 |
| Puddephatt, C | 1 |
| Grundy, C | 1 |
| Bohannon, J | 1 |
| Winogron, D | 1 |
| Burke, A | 1 |
| Babiker, A | 2 |
| Wilkes, H | 1 |
| Rauchenberger, M | 1 |
| Sheehan, S | 1 |
| Spencer-Drake, C | 1 |
| Taylor, K | 1 |
| Spyer, M | 1 |
| Ferrier, A | 1 |
| Naidoo, B | 1 |
| Dunn, D | 2 |
| Goodall, R | 2 |
| Peto, L | 1 |
| Nanfuka, R | 1 |
| Mufuka-Kapuya, C | 1 |
| Pillay, D | 1 |
| McCormick, A | 1 |
| Weller, I | 1 |
| Bahendeka, S | 1 |
| Bassett, M | 1 |
| Wapakhabulo, AC | 1 |
| Gazzard, B | 1 |
| Mapuchere, C | 1 |
| Mugurungi, O | 1 |
| Burke, C | 1 |
| Jones, S | 1 |
| Newland, C | 1 |
| Pearce, G | 1 |
| Rahim, S | 1 |
| Rooney, J | 1 |
| Smith, M | 1 |
| Snowden, W | 1 |
| Steens, JM | 1 |
| Breckenridge, A | 1 |
| McLaren, A | 1 |
| Hill, C | 1 |
| Matenga, J | 1 |
| Pozniak, A | 1 |
| Serwadda, D | 1 |
| Peto, T | 1 |
| Palfreeman, A | 1 |
| Borok, M | 1 |
| Gathe, J | 1 |
| Andrade-Villanueva, J | 1 |
| Santiago, S | 1 |
| Horban, A | 1 |
| Nelson, M | 1 |
| Cahn, P | 1 |
| Bogner, J | 1 |
| Spencer, D | 1 |
| Podzamczer, D | 3 |
| Yong, CL | 1 |
| Nguyen, T | 1 |
| Zhang, W | 1 |
| Drulak, M | 1 |
| Quinson, AM | 1 |
| Roxby, AC | 1 |
| Drake, AL | 1 |
| Ongecha-Owuor, F | 1 |
| Kiarie, JN | 1 |
| Richardson, B | 1 |
| Matemo, DN | 1 |
| Overbaugh, J | 1 |
| Emery, S | 1 |
| John-Stewart, GC | 1 |
| Wald, A | 1 |
| Farquhar, C | 1 |
| Prendergast, A | 2 |
| Tierney, J | 1 |
| Cotton, M | 1 |
| Gibb, D | 1 |
| Martínez, E | 2 |
| Arnaiz, JA | 2 |
| Dalmau, D | 2 |
| Ribera, E | 2 |
| Domingo, P | 2 |
| Knobel, H | 2 |
| Riera, M | 1 |
| Pedrol, E | 2 |
| Force, L | 2 |
| Llibre, JM | 1 |
| Segura, F | 1 |
| Richart, C | 1 |
| Cortés, C | 1 |
| Javaloyas, M | 1 |
| Aranda, M | 1 |
| Cruceta, A | 1 |
| de Lazzari, E | 2 |
| Gatell, JM | 2 |
| van Leth, F | 1 |
| Wit, FW | 1 |
| Reiss, P | 2 |
| Schattenkerk, JK | 1 |
| van der Ende, ME | 1 |
| Schneider, MM | 1 |
| Mulder, JW | 1 |
| Frissen, PH | 1 |
| de Wolf, F | 1 |
| Lange, JM | 2 |
| Macías, J | 1 |
| Castellano, V | 1 |
| Merchante, N | 1 |
| Palacios, RB | 1 |
| Mira, JA | 1 |
| Sáez, C | 1 |
| García-García, JA | 1 |
| Lozano, F | 1 |
| Gómez-Mateos, JM | 1 |
| Pineda, JA | 1 |
| Leyes, M | 1 |
| Asboe, D | 1 |
| Williams, IG | 1 |
| Goodall, RL | 1 |
| Hooker, MH | 1 |
| Mphatswe, W | 1 |
| Blanckenberg, N | 1 |
| Tudor-Williams, G | 1 |
| Thobakgale, C | 1 |
| Mkhwanazi, N | 1 |
| McCarthy, N | 1 |
| Walker, BD | 1 |
| Kiepiela, P | 1 |
| Goulder, P | 1 |
| Leng, LK | 1 |
| Pancharoen, C | 1 |
| Bunupuradah, T | 1 |
| Thisyakorn, U | 1 |
| Trinavarat, P | 1 |
| Sosothikul, D | 1 |
| Ananworanich, J | 1 |
| Berenguer, J | 1 |
| Bellón, JM | 1 |
| Miralles, P | 1 |
| Alvarez, E | 1 |
| Castillo, I | 1 |
| Cosín, J | 1 |
| López, JC | 1 |
| Sánchez Conde, M | 1 |
| Padilla, B | 1 |
| Resino, S | 1 |
| Richman, DD | 1 |
| D'Aquila, RT | 2 |
| Hughes, MD | 2 |
| Johnson, VA | 2 |
| Fischl, MA | 2 |
| Sommadossi, JP | 1 |
| Liou, SH | 1 |
| Timpone, J | 1 |
| Myers, M | 2 |
| Basgoz, N | 2 |
| Niu, M | 1 |
| Hirsch, MS | 2 |
| Bremer, JW | 1 |
| Elbeik, T | 1 |
| Erice, A | 1 |
| Kuritzkes, DR | 1 |
| Scott, WA | 1 |
| Spector, SA | 1 |
| Montaner, JS | 1 |
| Cooper, D | 1 |
| Vella, S | 1 |
| Harris, M | 1 |
| Conway, B | 1 |
| Wainberg, MA | 1 |
| Smith, D | 1 |
| Robinson, P | 1 |
| Hall, D | 1 |
| Doepel, L | 1 |
| Folkers, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada®[NCT00561925] | Phase 3 | 1,068 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine[NCT00000770] | Phase 2 | 400 participants | Interventional | Completed | |||
| A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease[NCT00001075] | 55 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00561925)
Timeframe: baseline, week 144
| Intervention | cells/cubic millimeter (Mean) |
|---|---|
| NVP IR 200mg BID | 239.3 |
| NVP XR 400mg QD | 270.7 |
(NCT00561925)
Timeframe: baseline, week 144
| Intervention | log10 copies/mL (Mean) |
|---|---|
| NVP IR 200mg BID | -2.7 |
| NVP XR 400mg QD | -2.8 |
Frequency of patients with hepatitis symptoms (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) |
|---|---|
| NVP IR | 10 |
| NVP XR | 8 |
| IR-IR/XR | 2 |
| XR-IR/XR | 0 |
Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation. (NCT00561925)
Timeframe: week 132
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| NVP IR | 4567.03 |
| NVP XR | 3634.26 |
Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 48
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non responder | |
| NVP IR 200mg BID | 384 | 122 |
| NVP XR 400mg QD | 409 | 96 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.012 | 0.022 | 0.024 | 0.026 | 0.026 | 0.026 | 0.026 | 0.029 | 0.029 | 0.032 | 0.038 |
| NVP XR | 0.000 | 0.002 | 0.010 | 0.016 | 0.018 | 0.018 | 0.018 | 0.020 | 0.022 | 0.022 | 0.022 | 0.022 | 0.026 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.012 | 0.049 | 0.059 | 0.063 | 0.063 | 0.067 | 0.070 | 0.076 | 0.076 | 0.076 | 0.076 |
| NVP XR | 0.000 | 0.002 | 0.014 | 0.026 | 0.034 | 0.036 | 0.036 | 0.043 | 0.049 | 0.056 | 0.058 | 0.058 | 0.070 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.006 | 0.027 | 0.033 | 0.039 | 0.039 | 0.042 | 0.044 | 0.053 | 0.053 | 0.053 | 0.053 |
| NVP XR | 0.000 | 0.000 | 0.002 | 0.006 | 0.008 | 0.008 | 0.008 | 0.015 | 0.019 | 0.028 | 0.031 | 0.033 | 0.033 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.002 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| NVP XR | 0.000 | 0.000 | 0.006 | 0.008 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | cumulative probability (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | |
| NVP IR | 0.000 | 0.000 | 0.034 | 0.067 | 0.081 | 0.093 | 0.113 | 0.130 | 0.156 | 0.172 | 0.192 | 0.202 | 0.213 | 0.229 | 0.243 | 0.267 | 0.275 | 0.289 |
| NVP XR | 0.000 | 0.000 | 0.026 | 0.046 | 0.059 | 0.067 | 0.083 | 0.115 | 0.139 | 0.156 | 0.162 | 0.176 | 0.188 | 0.206 | 0.218 | 0.232 | 0.236 | 0.244 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | proportion of participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | Interval Week 144 to <168 | |
| NVP IR 200mg BID | 0 | 0.006 | 0.006 | 0.023 | 0.029 | 0.029 | 0.031 | 0.04 | 0.042 | 0.047 | 0.047 | 0.052 | 0.054 | 0.054 | 0.057 | 0.057 | 0.06 | 0.06 | 0.062 |
| NVP XR 400mg QD | 0 | 0.002 | 0.006 | 0.008 | 0.01 | 0.019 | 0.021 | 0.025 | 0.025 | 0.027 | 0.027 | 0.032 | 0.035 | 0.04 | 0.04 | 0.045 | 0.047 | 0.047 | 0.047 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | proportion of participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | Interval Week 144 to <168 | |
| NVP IR 200mg BID | 1 | 0.84 | 0.838 | 0.834 | 0.834 | 0.832 | 0.83 | 0.822 | 0.806 | 0.792 | 0.777 | 0.759 | 0.733 | 0.713 | 0.686 | 0.662 | 0.65 | 0.63 | 0.61 |
| NVP XR 400mg QD | 1 | 0.865 | 0.865 | 0.865 | 0.863 | 0.861 | 0.859 | 0.848 | 0.832 | 0.816 | 0.808 | 0.788 | 0.766 | 0.745 | 0.719 | 0.697 | 0.681 | 0.671 | 0.66 |
(NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) | |
|---|---|---|
| DAIDS grade 3 or 4 AEs | DAIDS grade 4 AEs | |
| IR-IR/XR | 71 | 11 |
| NVP IR | 53 | 17 |
| NVP XR | 111 | 25 |
| XR-IR/XR | 8 | 3 |
Frequency of patients with drug related rash events by functional grouping (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| rash group I | rash group II | rash group IIA | rash group III | rash group IV | |
| IR-IR/XR | 6 | 3 | 1 | 0 | 0 |
| NVP IR | 9 | 6 | 4 | 3 | 0 |
| NVP XR | 11 | 13 | 5 | 5 | 0 |
| XR-IR/XR | 0 | 0 | 0 | 0 | 0 |
Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 144
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non responder | |
| NVP IR 200mg BID | 296 | 210 |
| NVP XR 400mg QD | 321 | 184 |
3 reviews available for nevirapine and Disease Exacerbation
| Article | Year |
|---|---|
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi | 2014 |
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi | 2012 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
13 trials available for nevirapine and Disease Exacerbation
| Article | Year |
|---|---|
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl | 2013 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Meth | 2010 |
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Adminis | 2011 |
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis | 2012 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug The | 2003 |
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Dis | 2007 |
A virological benefit from an induction/maintenance strategy: the Forte trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression; | 2007 |
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera | 2007 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Com | 1996 |
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1997 |
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; | 1998 |
8 other studies available for nevirapine and Disease Exacerbation
| Article | Year |
|---|---|
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte | 2013 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazi | 2014 |
The obstetric face and challenge of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf | 2009 |
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coho | 2004 |
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Disease Prog | 2004 |
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Pr | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progr | 2008 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To | 1997 |